AbbVie to Present IBD Research at Digestive Disease Week

AbbVie to Present IBD Research at Digestive Disease Week
Biopharmaceutical company AbbVie is going to present 18 abstracts regarding its gastroenterology and hepatology programs at the Digestive Disease Week (DDW), taking place between May 16th and 19th in Washington, D.C. Among the abstracts, AbbVie will feature data on clinical studies conducted by the company to assess the safety and efficacy of HUMIRA (adalimumab), a treatment for Crohn's disease and ulcerative colitis. AbbVie will feature the results of its six-year, observational study which included patients who suffer from moderate to severe Crohn's disease, in a presentation entitled "An Observational Study of Adalimumab in Crohn's Disease: Results at Year 6; G. D'Haens, et al." In addition, a post hoc investigation of moderate to severe ulcerative colitis patients regarding  the durability of clinical remission and response will also be presented at "Durable Clinical Remission and Response in Adalimumab-Treated Patients with Ulcerative Colitis; R. Panaccione, et al." A further presentation entitled "Effect of Adalimumab on Clinical Laboratory Parameters in Pediatric Crohn's Disease Patients from IMAgINE 1; J. Hyams, et al." will be hosted featuring research into the indirect costs and family burden of U.S. pediatric patients with Crohn's disease. A study that compared the burden experienced by ulcerative colitis and Crohn's patients and another one on the severity of ulcerative colitis are 
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *